MX2022006941A - Epítopos de y anticuerpos contra trpv1. - Google Patents

Epítopos de y anticuerpos contra trpv1.

Info

Publication number
MX2022006941A
MX2022006941A MX2022006941A MX2022006941A MX2022006941A MX 2022006941 A MX2022006941 A MX 2022006941A MX 2022006941 A MX2022006941 A MX 2022006941A MX 2022006941 A MX2022006941 A MX 2022006941A MX 2022006941 A MX2022006941 A MX 2022006941A
Authority
MX
Mexico
Prior art keywords
antibodies
trpv1
epitopes
relates
immunoconjugates
Prior art date
Application number
MX2022006941A
Other languages
English (en)
Inventor
Carolina Trkulja
Owe Orwar
Max Davidson
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2022006941A publication Critical patent/MX2022006941A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a anticuerpos que se unen a TRPV1. La invención también se refiere a ciertos epítopos de la proteína TRPV1. La invención también se refiere a inmunoconjugados y composiciones que comprenden tales anticuerpos. La invención también proporciona métodos para producir tales anticuerpos. La invención proporciona además el uso de dichos anticuerpos con fines terapéuticos, por ejemplo, en el tratamiento del dolor.
MX2022006941A 2019-12-10 2020-12-10 Epítopos de y anticuerpos contra trpv1. MX2022006941A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1918103.1A GB201918103D0 (en) 2019-12-10 2019-12-10 Epitopes and antibodies
PCT/EP2020/085629 WO2021116341A1 (en) 2019-12-10 2020-12-10 Trpv1 epitopes and antibodies

Publications (1)

Publication Number Publication Date
MX2022006941A true MX2022006941A (es) 2022-09-29

Family

ID=69172152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006941A MX2022006941A (es) 2019-12-10 2020-12-10 Epítopos de y anticuerpos contra trpv1.

Country Status (13)

Country Link
US (1) US20230322916A1 (es)
EP (1) EP4073118A1 (es)
JP (1) JP2023506433A (es)
KR (1) KR20220123240A (es)
CN (1) CN115244083A (es)
AU (1) AU2020403105A1 (es)
BR (1) BR112022011122A2 (es)
CA (1) CA3159521A1 (es)
GB (1) GB201918103D0 (es)
IL (1) IL293641A (es)
MX (1) MX2022006941A (es)
WO (1) WO2021116341A1 (es)
ZA (1) ZA202205813B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202019522D0 (en) * 2020-12-10 2021-01-27 Oblique Therapeutics Ab Epitopes and antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
WO1999009140A1 (en) * 1997-08-20 1999-02-25 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
EP1175504A4 (en) * 1999-04-15 2002-07-31 Ortho Mcneil Pharm Inc DNA WHICH CODES THE VANILLOID RECEPTOR VR1
GB201617002D0 (en) * 2016-10-06 2016-11-23 Oblique Therapeutics Ab Multi-protease method

Also Published As

Publication number Publication date
BR112022011122A2 (pt) 2022-09-06
AU2020403105A1 (en) 2022-06-16
EP4073118A1 (en) 2022-10-19
KR20220123240A (ko) 2022-09-06
GB201918103D0 (en) 2020-01-22
JP2023506433A (ja) 2023-02-16
CN115244083A (zh) 2022-10-25
WO2021116341A1 (en) 2021-06-17
CA3159521A1 (en) 2021-06-17
IL293641A (en) 2022-08-01
ZA202205813B (en) 2023-10-25
US20230322916A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2022010306A (es) Epitopos y anticuerpos del homologo del oncogen viral del sarcoma de la rata kirsten (kras).
PH12020551447A1 (en) Antibodies
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2022010621A (es) Anticuerpos anti-cd19 humano.
NZ762312A (en) Anti-pacap antibody
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
EA202092151A1 (ru) Антитела
MX2022009130A (es) Anticuerpos anti-e-selectina, composiciones y metodos de uso.
EA202092279A1 (ru) Антитела к mica и/или micb и их применение